KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cvs Health (CVS) Total Liabilities (2016 - 2025)

Cvs Health (CVS) has disclosed Total Liabilities for 17 consecutive years, with $178.2 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities changed 0.38% year-over-year to $178.2 billion, compared with a TTM value of $178.2 billion through Dec 2025, changed 0.38%, and an annual FY2025 reading of $178.2 billion, changed 0.38% over the prior year.
  • Total Liabilities was $178.2 billion for Q4 2025 at Cvs Health, down from $182.2 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $182.2 billion in Q3 2025 and bottomed at -$71.5 billion in Q3 2022.
  • Average Total Liabilities over 5 years is $157.7 billion, with a median of $174.3 billion recorded in 2023.
  • The sharpest move saw Total Liabilities tumbled 144.6% in 2022, then skyrocketed 347.31% in 2023.
  • Year by year, Total Liabilities stood at $157.6 billion in 2021, then decreased by 0.71% to $156.5 billion in 2022, then grew by 10.6% to $173.1 billion in 2023, then grew by 2.54% to $177.5 billion in 2024, then rose by 0.38% to $178.2 billion in 2025.
  • Business Quant data shows Total Liabilities for CVS at $178.2 billion in Q4 2025, $182.2 billion in Q3 2025, and $180.8 billion in Q2 2025.